Wassil Jim 4

What Happened

• Wassil Jim, Chief Operating Officer of Vaxcyte, sold a total of 2,250 shares on April 1, 2026 in two open-market transactions: 1,412 shares at a weighted-average price of $58.14 ($82,091) and 838 shares at a weighted-average price of $58.93 ($49,385), for combined proceeds of about $131,476. These sales were reported on a Form 4 filed April 3, 2026.

Key Details

• Transaction dates: April 1, 2026 (reported Apr 3, 2026; appears filed within the standard 2-business-day window).
• Prices: weighted-average prices $58.14 (range $57.695–$58.69) and $58.93 (range $58.74–$59.215); full breakdown by price available upon request per the filing.
• Total shares sold: 2,250; total proceeds ≈ $131,476.
• Shares owned after transaction: Not specified in the provided Form 4.
• Notable footnotes: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted Dec 9, 2025 (routine plan-based selling). The filing also notes prior transfers under a divorce settlement (962 and 612 shares transferred on Mar 25–26, 2026); those disposed shares will not be reported as beneficially owned in future Section 16 filings.

Context

• These were sales (often routine for insiders, especially when executed under a pre-established 10b5-1 plan) and do not by themselves indicate company outlook. The filing includes a domestic relations order-related transfer in late March, which affected beneficial ownership reporting going forward.